Details for New Drug Application (NDA): 210063
✉ Email this page to a colleague
The generic ingredient in FULVESTRANT is fulvestrant. There are twelve drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the fulvestrant profile page.
Summary for 210063
Tradename: | FULVESTRANT |
Applicant: | Teva Pharms Usa Inc |
Ingredient: | fulvestrant |
Patents: | 0 |
Formulation / Manufacturing: | see details |
Pharmacology for NDA: 210063
Mechanism of Action | Estrogen Receptor Antagonists Selective Estrogen Receptor Modulators |
Suppliers and Packaging for NDA: 210063
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
FULVESTRANT | fulvestrant | SOLUTION;INTRAMUSCULAR | 210063 | NDA | Actavis Pharma, Inc. | 0591-5019 | 0591-5019-02 | 2 SYRINGE, GLASS in 1 CARTON (0591-5019-02) / 5 mL in 1 SYRINGE, GLASS (0591-5019-11) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAMUSCULAR | Strength | 250MG/5ML (50MG/ML) | ||||
Approval Date: | Aug 19, 2019 | TE: | RLD: | No |
Complete Access Available with Subscription